Assembly Biosciences is advancing a new class of oral therapeutics for the treatment of hepatitis B (HBV) infection and novel oral live biotherapeutics for disorders associated with the microbiome.
Copyright West LLC. Minimum 15 minutes delayed.
- Data for Assembly Biosciences’ First and Second Generation HBV Core Inhibitors in Development for the Treatment of Chronic Hepatitis B Highlighted in Late-Breaker Poster Session at AASLD 2019
- Assembly Biosciences Reports Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
- Assembly Biosciences Reports Third Quarter 2019 Financial Results and Recent Highlights